Background: The role of the hematologic indicators in the identification of severe or critical patients requires further investigation. In this study, we focused on predicting Covid-19 patients at risk of progression using blood parameters.
Materials And Methods: We performed a retrospective study including 444 patients with confirmed Covid-19. Hematological parameters were evaluated. The logistic regression analysis was performed with step-wise method with dependent variables such as intensive care units admission, partial pressure of oxygen saturation, and mortality. Also, independent variables such as hematological parameters, age and sex to assess variables that are likely to predict patients at risk of progression.
Results: Patients in intensive care units had significantly higher mean absolute neutrophil count than outpatients ( < 0.001). There was a statistically significant difference in the mean absolute lymphocyte count between dead and survived patients ( = 0.015). Multivariate analysis confirmed the positive association of the white blood cells ( < 0.001), absolute neutrophil count ( < 0.004), red cell distribution width ( < 0.001), and lactate dehydrogenase ( = 0.007) to be positively associated with the admission of Covid-19 patients in the intensive care units and the absolute monocyte count ( = 0.012, Odds ratios = 0.100, CI95% = 0.066-0.605) to be negatively associated with mortality.
Conclusion: Based on the results of our study, it is recommended to use hematological data to make clinical decisions and evaluate the patient's prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331539 | PMC |
http://dx.doi.org/10.4103/abr.abr_174_22 | DOI Listing |
Clin Exp Med
December 2024
Discovery Research, Scientific Innovation Office, Grifols, Palou 3, 08150, Parets del Vallès, Barcelona, Spain.
Hemophilia A (HA) patients under emicizumab prophylaxis may require the concomitant use of procoagulant factors for breakthrough bleedings or immune tolerance induction (ITI). The aim of this study is to evaluate the ex vivo procoagulant effect of plasma-derived FVIII concentrates containing von Willebrand factor (pdFVIII/VWF) in samples from patients with severe HA without inhibitors on emicizumab prophylaxis. Samples from healthy controls (HC) and HA patients were drawn in sodium citrate plus corn trypsin inhibitor tubes and spiked with increasing concentrations of pdFVIII/VWF concentrates (10-400 IU/dL) (Fanhdi/Alphanate, Grifols), activated prothrombin complex concentrate (aPCC, 0.
View Article and Find Full Text PDFInt J Lab Hematol
December 2024
Institute of Medical Genetics and Pathology, University of Basel Hospital, Basel, Switzerland.
Introduction: Investigation of bone marrow (BM) trephine biopsies and/or clot sections by CD34 immunohistochemistry (IHC) testing has been used by pathologists for several decades, and its clinical value has been well established with QBEND10 being the most frequently used primary antibody (Ab) clone. However, most other parameters related to the IHC protocol as well as the readout vary widely between clinical laboratories and in the published literature. The ICSH Working Group having reviewed the published evidence has established guidelines that will help to harmonize performance and reporting of CD34 IHC on BM biopsies.
View Article and Find Full Text PDFClin Ther
December 2024
Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Purpose: The pharmacokinetic (PK) profile of direct-acting antivirals, namely ledipasvir/sofosbuvir (LDV/SOF), might be altered in patients with acute lymphoblastic leukemia (ALL), affecting the optimum dose needed for hepatitis C virus treatment. Limited data are available evaluating the population PK of LDV/SOF and SOF metabolite GS-331007. We aimed to study whether ALL could affect population PK parameters of LDV, SOF, and the SOF major metabolite GS-331007 in hepatitis C virus-infected children, develop and validate a predictive PK model of LDV/SOF disposition in this special population, and identify their explained and unexplained sources of variability.
View Article and Find Full Text PDFAnn Oncol
December 2024
University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) and German Hodgkin Study Group (GHSG), Cologne, Germany; Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address:
Background: We aimed to evaluate the correlation of progression-free (PFS) and overall survival (OS) after first-line treatment of classical Hodgkin lymphoma (HL) and the potential of PFS to serve as a surrogate parameter for OS.
Patients And Methods: We analyzed individual patient data obtained during and after treatment with polychemotherapy within nine randomized phase III trials (GHSG HD7-HD15) between 01/93 - 08/18. Effects of 16 experimental treatments on PFS and OS on trial level were evaluated by estimation of the treatment effects with Cox proportional hazards (PH) regression and a linear weighted least squares regression.
Aquat Toxicol
December 2024
Department of Animal & Poultry Production, Faculty of Technology and Development, Zagazig University, Zagazig, 44511, Egypt.
This study aims to examine the restorative impact of corn cob biochar (CCB) on pendimethalin (PMD)-induced toxicity in Oreochromis niloticus. Fish were divided into four groups: the first control group without treatment, the second group (CCB) exposed to 10 g CCB/L, the third group (PDM) exposed to 0.355 mg PDM/L, and the fourth group (PDM+ CCB) receiving both 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!